Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Psychiatry. 1997;58 Suppl 10:7-12.Links

Efficacy of olanzapine: an overview of pivotal clinical trials.

Psychopharmacology Division, Eli Lilly and Company, Indianapolis, IN 46285, USA.

Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similar to the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies, which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest that olanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidol for the treatment of the negative symptoms of schizophrenia.

PMID: 9265910 [PubMed - indexed for MEDLINE]